Our Commitment to Patients
Spectrum’s core mission is to bring pharmaceutical products to patients for unmet medical needs. To this mission, we bring our years of drug development expertise, coupled with the insight of working in many different oncology indications. Learn more >
Spectrum and its subsidiaries have six marketed oncology/hematology products, three for different types of non-Hodgkins lymphoma, one for advanced metastatic colorectal cancer, one for a certain type of acute lymphoblastic leukemia (ALL) and one for multiple myeloma. There are two products in late-stage development, as well as a broad and diversified portfolio of proprietary drugs in various stages of development, all with a focus on oncology and hematology. Learn more >
Wednesday November 8, 2017
Thursday November 2, 2017
Monday October 30, 2017
Expanding Patient Options
Our passion to deliver additional options for patients suffering from cancer is behind every action we take.
We will work to understand their needs and develop new and innovative therapies that offer hope for improved disease outcomes. Learn more about the Spectrum philosophy.
Patient Assistance (STAR)
This Web site contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and in reliance upon the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based on the beliefs of the Company’s management as well as assumptions made by and information currently available to the Company’s management. Readers should not put undue reliance on these forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Spectrum Pharmaceuticals, Inc.’s actual results may differ materially from the results projected in the forward-looking statements. Factors that might cause such a difference include, but are not limited to, those discussed in the Company’s most recent Form 10-K and 10-Qs. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this filing except as required by law.